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Introduction
Alzheimer’s disease is the most common cause of dementia in the 
elderly (Seeley, Miller 2015) and a devastating disease for those af-
fected and their families. According to the Alzheimer’s Association, 
Alzheimer’s disease affected 5.4 million American people in 2016. 
Age is a major risk factor for developing Alzheimer’s, and the risk 
increases the longer a person lives past age 60. A person over 
the age of 65 has a one in nine chance of having the disease. 
These numbers will only increase in the future years. Because of 
advancing science and better treatments, people are living lon-
ger, therefore increasing the chances of developing this disease. 
The average cost of caring for a person with Alzheimer’s is over 
$50,000 a year, creating an emotional and financial burden on 
caregivers and family members (Seeley, Miller 2015).  
Alzheimer’s disease progresses in stages, and the first symptoms 
noted are generally memory related. The disease is usually diag-
nosed in the “mild” stage, where memory loss becomes more 
apparent and the patient exhibits other cognitive impairments 
(NIH). It is important to note that these are not symptoms of 
normal aging; this is evidence of a disease state in the brain (CDC). 
As the disease progresses to moderate and severe Alzheimer’s, 
the patient gradually loses language ability, reasoning, sensory 
processing and conscious thought. The disease culminates in the 
patient being completely uncommunicative and bedridden, wholly 
dependent on a caregiver (NIH). The disease usually lasts for 8-10 
years and ends in death from secondary factors, such as malnutri-
tion or pneumonia. This pattern of degeneration is patterned by 
the atrophy of brain tissue, which begins in the medial temporal 
lobes, then affecting the lateral parietal, medial parietal and tem-
poral lobes before spreading to the lateral frontal cortex, as seen 
by brain imaging of Alzheimer patients (Seeley, Miller 2015). 
The brain tissue of an Alzheimer patient exhibits significant shrink-
age and characteristic amyloid plaques and neurofibrillary tangles 
(Seeley, Miller 2015). Amyloid plaques consist of beta-amyloid 
oligomers that stick together. These beta-amyloid fragments arise 
from a transmembrane protein called amyloid precursor protein 
(APP). Different enzymes called alpha-secretase, beta-secretase, 
and gamma-secretase can cleave the APP protein in different plac-
es causing different results. In a healthy pathway, alpha-secretase 
will cleave off a fragment called sAPPα, which may be beneficial 
to the neuron. The rest of the APP fragment is cleaved with gam-
ma-secretase and released. In the harmful pathway, APP is cleaved 
with beta-secretase which releases sAPPβ. The residual fragment 
is cleaved with gamma-secretase and is released as amyloid-β. 
These amyloid-β fragments accumulate and become the damag-
ing amyloid plaques found in Alzheimer patients (NIH).
Another feature of Alzheimer’s disease is the neurofibrillary tan-
gles caused by the protein tau, which normally helps support the 
internal structure of the neurons. Neurons contain microtubules, 
which support them and help in transporting nutrients. Attached 
to these microtubules are the tau proteins that aid in stabilization. 
In Alzheimer’s the tau proteins are hyperphosphorylated, which 
causes the tau proteins to separate from the microtubules and 
tangle together with other tau threads. The microtubules break 
down which causes the neuron’s transport system to fail, com-
promising the neuron’s ability to communicate (NIH).
These misfolded proteins cause the degradation of neurons in 
Alzheimer’s and the subsequent brain atrophy. The causes and possi-
ble treatments for the accumulation of beta-amyloid and the neuro-
fibrillary tangles are the subjects of ongoing research. This paper ex-
plores three different current ideas as to what causes these plaques 
and tangles to form, and by what mechanism they cause disease.
Methods
Articles and studies researched in this paper were obtained 
through the Ebsco and AccessMedicine databases with access 
provided by Touro College Library. Pubmed and Google Scholar 
were used to find other research articles. Several papers were 
obtained by use of the Touro College interlibrary loan system. 
Some of the research articles were kindly provided by Dr. Zev 
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Leifer, who has an interest in the topic. In addition, references 
in these articles were used as additional sources of information.
The Effect of apoE on the Development of Senile 
Plaques
Several possible causes of Alzheimer’s disease are currently 
under investigation. Recent research has been done to study ge-
netic factors of the disease. It has been found that the apolipo-
protein E (apoE) gene exists in several alleles, and one, in partic-
ular, contributes to the biochemical mechanism of Alzheimer’s 
disease (Liraz et al., 2013). Alzheimer’s disease is characterized 
by the formation of senile plaques composed of amyloid-β, a 
40-42 amino acid long peptide derived from amyloid precursor 
protein. Another feature is the neurofibrillary tangles that arise 
from the hyperphosphorylated protein tau, which leads to a 
compromised cytoskeleton and cell death. The apoE gene en-
codes for the apoE protein, which is produced by astrocytes in 
the brain. It is an important cholesterol carrier which is involved 
in the transport of lipids and injury repair. ApoE exists as three 
alleles: apoE2, apoE3, and apoE4. ApoE is a 299 amino acid pro-
tein, and the difference between the isoforms is at amino acid 
112 and 158, where either a cysteine or arginine is present (Lui 
et al., 2013). This slight difference is enough to cause a change 
in the protein’s tertiary structure, which affects its ability to 
bind lipids, receptors, and amyloid-β. ApoE3 is the most com-
mon allele, and apoE2 is associated with a decreased risk of AD 
(Simonovitch, et al., 2016). ApoE4 is a hypolipidated version of 
the protein, and it has been linked to an increased risk of devel-
oping Alzheimer’s. A greater percentage of the apoE4 allele has 
been noted in families with late-onset and sporadic Alzheimer’s. 
In sporadic AD, the frequency of apoE4 is greater than 50%, and 
each copy of the allele decreases the disease onset 7-9 years. 
Patients with a higher percentage of apoE4 have been found to 
have a higher level accumulated amyloid-β and hyperphosphor-
ylated tau, as well as a decreased neural plasticity and neuropa-
thology (Liraz et al., 2013). The fact that amyloid-β accumulation 
is increased in apoE4 positive patients led researchers to believe 
that the two pathways interact with each other, and cross-talk 
between them causes the pathological effects. The presence of 
the apoE4 allele adversely affects the binding of apoE4 to lipids, 
leading to the proposal that the disease is caused by lipid-relat-
ed mechanisms (Liraz et al., 2013).
Impaired Autophagy in Alzheimer’s Disease
Additional research on how apoE4 is related to Alzheimer’s 
disease has shown how other factors can also play a role in 
the disease process. Besides causing the formation of senile 
plaques, the apoE4 protein can also impede the body’s means of 
removing it. Amyloid plaques and neurofibrillary tangles are usu-
ally removed from the brain through the process of autophagy 
(Simonovitch et al., 2016, p. 917). Autophagy clears out cellular 
debris such as dysfunctional organelles, old proteins, and aggre-
gated proteins. Normally astrocytes produce apoE in the central 
nervous system, which protects the brain from harmful protein 
buildup. However, the mechanism becomes faulty as the disease 
progresses, and impaired autophagy may become harmful be-
cause the accumulated protein can cause synaptic degeneration 
in hippocampal neurons. In 2016, an experiment was done to 
connect the presence of the apoE4 gene to the accumulation of 
amyloid-β buildup by the process of decreased autophagy. This 
experiment used knock-in mice with either apoE3 or apoE4 
human cell lines and 5XFAD mice to replicate the disease 
process. 5XFAD mice have a phenotype similar to Alzheimer 
disease and exhibit many comparable characteristics such as 
amyloid plaques (Alzforum). Astrocytes were isolated from the 
apoE3 and apoE4 mice and cultured with frozen coronal brain 
sections from the 5XFAD mice. The experimental results were 
based on the ability of the astrocytes to clear the amyloid-β 
plaques from the brain slices. Brain slices with no astrocytes 
were used as a control. Amino acid deprivation was used to 
induce autophagy, and results were measured at the first, sec-
ond and fourth hours of starvation. Results were calculated by 
means of the LC3 and p62/SQSTM1 proteins. LC3-I becomes 
a lipidated form, LC3-II, during autophagy and becomes asso-
ciated with the autophagosomal membrane. P62 is a protein 
that is associated with LC3 and is degraded during autopha-
gy. By looking at the LC3-II/LC3-I ratio, the rate of activation 
of autophagy can be monitored and measured. A higher ratio 
indicates greater autophagic activation, which in turn indicates 
more autophagy and more clearing of the amyloid plaques. This 
ratio was significantly higher in the apoE3 astrocytes compared 
to the apoE4 astrocytes. In addition, the levels of p62 decreased 
more rapidly in the apoE3 astrocytes compared to the apoE4 
astrocytes following starvation. This evidence suggests that the 
initiation of autophagy in apoE4 astrocytes is somehow im-
paired in Alzheimer’s disease (Simonovitch et al., 2016). 
To test this hypothesis, the researchers examined the autophagy 
levels of the astrocytes when an autophagy inducer and inhibi-
tor were added in separate experiments. Rapamycin was used 
as an autophagy inducer, and chloroquine was used as an inhib-
itor. In these sets of experiments, the apoE3 and apoE4 astro-
cytes were treated with rapamycin and chloroquine in separate 
trials. The results were measured with the LC3-II/LC3-I ratio 
and the rate of p62 degradation. The results showed that with 
treatment with rapamycin, the apoE3 cells were even more ef-
fective at clearing the amyloid-β plaques, and while it was more 
effective than the apoE4, the apoE4 was still more effective than 
the non-treated apoE4 cells. In contrast, treatment with chlo-
roquine entirely prevented autophagy in both apoE3 and apoE4 
cells (Simonovitch et al., 2016)  This research highlights how the 
apoE gene can be connected to the buildup of the amyloid-β 
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plaques in Alzheimer’s disease. It demonstrates that the pres-
ence of the apoE4 allele affects the body’s mechanisms of natu-
rally clearing protein buildup through the process of autophagy 
and that the problem is probably at the beginning of the process 
when autophagy is first induced. This research shows that not 
only is Alzheimer’s disease caused by the buildup of misfolded 
proteins but also that the body’s normal mechanism of clearing 
it away is also adversely affected.
ABCA1 Lipidates ApoE
Knowing how the function of apoE4 is different from apoE3 
is valuable for possible therapeutic strategies. If apoE4 can be 
made to function like apoE3, many of the symptoms and pa-
thologies of Alzheimer’s disease can potentially be reversed. 
Although the full pathological process of apoE4 is not yet fully 
understood, evidence suggests that it is connected to lipid-re-
lated mechanisms (Boehm-Cagan et al., 2016). ApoE lipidation 
is controlled by the ATP-binding cassette transporters ABCA1 
and ABCG1. ABCA1 triggers the efflux of cholesterol and phos-
pholipids onto the apoE acceptor, and ABCG1 has a similar 
function. Studies have shown that apoE4 is less lipidated than 
apoE3 and is less effective at stimulating the efflux of cholester-
ol and phospholipids in a cell culture. These proteins are regu-
lated by the retinoid X receptor transcription regulating system. 
If this system can be activated by some means, the pathological 
effects of apoE4 may be alleviated.
CS-6253 Can Activate ABCA1
CS-6253 is a non-toxic peptide derived from the carboxyl ter-
minal of apoE (Boehm-Cagan et al., 2016). It has been shown to 
interact with and stimulate ABCA1 to activate cholesterol and 
phospholipid efflux. A study was done to see what effect CS-
6253 has in vivo on the neuropathology and cognitive decline 
in apoE4 mice. ApoE3 and apoE4 mice were injected intraper-
itoneally with CS-6253 every 48 hours for 6 weeks. A control 
group was injected with saline. They were then subjected to 
a series of cognitive tests to measure learning and memory. 
During the novel object recognition test, mice were placed in 
an arena with no objects. Then, two objects were introduced. 
24 hours later the mice were replaced in the arena with one 
familiar object, and one new one. Their behavior and interac-
tions with the objects were monitored and measured. During 
the Morris maze test, the mice were placed in a circular pool 
of cloudy water with a submerged hidden platform. The test 
examined the mice’s memory by measuring the time it took 
the mice to reach the platform after being placed in the pool 
previously. After the experiment, the mice were euthanized and 
the brains were removed to be stained and studied (Boehm-
Cagan et al., 2016).
The results of this experiment showed many important find-
ings on the effect of CS-6253. Treatment with CS-6253 sig-
nificantly lowered the buildup of amyloid-β in the test apoE4 
mice compared to the untreated mice. The levels of amyloid-β 
in the treated apoE4 mice brains became similar to the un-
treated apoE3 mice, who were unaffected by the treatment. 
Treatment with CS-6253 also had an effect on the buildup of 
phosphorylated tau. The tested apoE4 mice showed a marked 
decrease of phosphorylated tau compared to the untreated 
apoE4 mice. Injections of CS-6253 also affected the results 
of the cognitive tests. Before treatment, apoE4 mice took a 
significantly longer time to reach the platform in the Morris 
maze test compared to the apoE3 mice. After treatment, the 
performance of the treated apoE4 mice was similar to the 
apoE3 mice. The treated apoE4 mice also scored similarly to 
the apo3 mice during the novel item recognition test after they 
were treated with CS-6253. The experimental findings show 
that CS-6253 can successfully activate ABCA1 to reverse the 
hypolipidation of apoE4, decrease the levels of accumulated 
amyloid-β and phosphorylated tau, and reverse the cognitive 
deficiencies of apoE4 mice. These results indicate that ABCA1 
can be an important therapeutic target in treating Alzheimer’s 
disease (Boehm-Cagan et al., 2016).
Alzheimer’s Nay be Linked to Prion Diseases
Many characteristics of Alzheimer’s disease are similar to prion 
diseases, suggesting that there may be a connection between 
the two (Castellani et al., 2004). Prion diseases are charac-
terized by the buildup of misfolded prion proteins (PrP) that 
can propagate themselves by causing other healthy protein to 
misfold in the same way (Prion Alliance). Prion diseases can 
affect humans and animals. The five human prion diseases are 
Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker 
syndrome, fatal familial and sporadic insomnia, kuru, and new 
variant Creutzfeldt-Jakob disease. Alzheimer’s disease is similar 
to these prion diseases in that both have an age requirement for 
the symptoms to become apparent, both usually occur sporadi-
cally although there is a genetic component in some cases. Most 
prion diseases appear in middle age to older patients, and that 
is the age demographic that is affected by Alzheimer’s. There 
is significant overlap between the two diseases’ characteristics. 
In both diseases, there is allelic segregation, with an allele that 
makes a person susceptible to getting the disease. In prion dis-
ease, this gene is the PRNP gene, and in Alzheimer’s disease, it 
is ApoE and presenilin 1 genes. Furthermore, in a certain type 
of Gerstmann-Straussler-Scheinker syndrome, prion plaques in 
the gray matter also have tau protein with neurofibrillary tan-
gles, amyloid-β accumulation, and gradual memory loss over a 
longer span of time than typical prion diseases, more similar to 
the pattern seen in Alzheimer’s disease (Castellani et al., 2004).
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The word prion comes from “proteinaceous infectious par-
ticle” (Jeffrey 2013). These particles are neither bacteria nor 
virus, but they cause transmissible diseases. Prion diseases 
are also known as “transmissible spongiform encephalopa-
thies” because they are neurodegenerative and ultimately 
fatal. Amyloid plaques are frequently present in these diseases, 
which leads to the possibility that Alzheimer’s disease may be 
related. Prions are caused by a pathogenic form of cellular 
prion proteins (PrPc), which are encoded by the host’s PRNP/
prnp gene (Jeffrey 2013). PrPC is an endogenous, cell surface 
glycoprotein of unknown function (Elezgarei, Biasini 2016). In 
prion diseases, this normal protein undergoes a conforma-
tional change and is called a “scrapie form of PrP,” or PrPSc. 
This misfolded isomer accumulates in the central nervous 
system of affected individuals. PrPSc, or prions, are capable 
of propagating themselves by binding to normal PrPC pro-
teins and forcing their conformational change to new PrPSc, 
thereby perpetuating a cycle that leads to a buildup of misfold-
ed proteins, which causes neurodegeneration and cell death 
(Elezgarei, Biasini 2016).  PrPSc changes PrPC into prions by 
affecting the tertiary structure of the protein.  Normal PrP is 
made up of 209 amino acids and the tertiary structure is 40% 
alpha helix with minimal beta sheet. PrPSc however, is made of 
40% beta sheet and 30% alpha helix (Castellani et al., 2004). 
Research shows that the prions are formed when alpha helixes 
are converted into beta sheets. This change causes PrPSc to 
be insoluble and resistant to proteolytic enzymes (Castenelli 
et al., 2004). 
Similarities Between Amyloid-β and Prions
Amyloid-β oligomers in Alzheimer’s disease have similarities to 
prions. Soluble amyloid-β oligomers affect the neuronal synapse 
in Alzheimer’s disease, causing synaptic abnormalities and neu-
rodegeneration (Elezgarei, Biasini 2016). These oligomers are 
different from the insoluble amyloid-β that builds up in the brain. 
There is evidence that the amyloid-β oligomers bind to PrPC in 
a similar manner to prions, and cause a cascade that leads to cell 
death (Laurén et al., 2009). PrPC can act as a receptor site on 
the cell membrane of neurons, which have been shown to bind 
amyloid-β and mediate the pathological effect. Suppression of 
these receptors may, in fact, have therapeutic benefit for people 
suffering from the disease (Laurén et al., 2009) PrPC-amyloid-β 
complexes occur in the brains of Alzheimer patients, which is 
further evidence that this prion-like mechanism is implicated 
in Alzheimer’s disease. PrPC is not necessarily involved in all 
cases of Alzheimer’s; Amyloid-β can cause neural damage with-
out PrPC (Elezgarei, Biasini 2016). This fact demonstrates the 
complexity of the disease and that the cause may be due to 
several factors. There are several similarities between amyloid-β 
precursor protein (AβPP) in Alzheimer’s disease and PRNP in 
prion diseases (Castenelli et al., 2004). Mutations in both of 
these genes can cause a buildup of their respective proteins 
with increased beta sheet structure.
Disease Transmission
Classic prion diseases are transmissible from one affected in-
dividual to another. They are able to be passed from person to 
person, from animal to person, and from person to animal. PrPSc 
initially forms in sporadic diseases by nucleation. The initial for-
mation of the protein is kinetically less favorable; however, once 
it overcomes the activation barrier it is able to propagate, chang-
ing PrPC to PrPSc very easily (Beekes et al., 2014). Once you 
have an initial prion “seed,” it can quickly proliferate and corrupt 
other proteins (Figure 1). However, prions are not infectious in 
the typical sense; you cannot “catch” a prion disease through 
direct contact (Weissmann et al., 2002). Transmission of prions 
occurs perorally and perenterally. The kuru epidemic that oc-
curred in Papua New Guinea in the 1900’s was spread through 
cannibalism. A greater concern is the spread of prions to hu-
mans iatrogenically. Prion contaminated cadaver-derived human 
growth hormone gonadotrophin has caused Creutzfeldt-Jakob 
disease in people in the past, and surgical instruments that have 
been used on affected people have caused the disease in oth-
ers, even after being properly sterilized. If Alzheimer disease is 
so similar to prion diseases, can Alzheimer’s be spread through 
such means? Studies were done where amyloid-β taken from 
the brain tissue of Alzheimer’s patients was injected into mice 
(Kane et al., 2000). This resulted in the stimulation of amyloid-β 
deposition in mice that were genetically predisposed to the for-
mation of such plaques. Amyloid-β deposition was recovered 
past the site of injection, similar to prion spreading. Inoculation 
of amyloid-β in wild-type mice initiated amyloid-β build up in 
brain tissue at the site of injection, and in certain species, in 
distant areas of the brain as well. However, none of the mice 
developed cerebral neurodegeneration or cognitive decline 
(Beekes et al., 2014). Similar experiments were done with the 
protein tau (Sanders et al., 2014). The protein was able to repli-
cate itself with high fidelity in a prion-like manner and cause an 
increase of hyperphosphorylated tau in the mouse brain tissue. 
Nevertheless, this buildup of tau did not cause cognitive decline 
or severe disease in these mice. Epidemiological studies investi-
gated the transmission of Alzheimer’s disease between humans 
in real life (Beekes et al., 2014). Available data indicates that 
Alzheimer’s disease is not likely to be spread between people. 
Blood transfusions do not cause a risk of Alzheimer’s in the re-
cipient, and neither does plasma protein therapy for hemophil-
ia. Another study examined the risk associated with receiving 
cadaveric human growth hormone, derived from the pituitary 
gland of the deceased. Such growth hormone has caused over 
200 cases of iatrogenic Creutzfeldt-Jakob disease because of 
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PcPSc seeds that contaminated the hormone and caused the 
prion disease in the recipient. In this study, researchers found 
small amounts of amyloid-β in the pituitary glands of the recip-
ient. Yet, none of the recipients studied developed Alzheimer’s 
disease. Based on these studies, as similar as Alzheimer’s dis-
ease is to prion diseases, there is an essential difference when 
it comes to disease transmission. Although seeding effects of 
Amyloid-β can somewhat cause neurotoxicity, it does not cause 
the neurodegenerative a cognitive impairment characteristic of 
Alzheimer’s (Beekes et al., 2014).
Environmental Effects on Neurodegenerative 
Disease: Mystery Disease in Guam is Similar to 
Alzheimer’s
The environment can have a role in the development of neu-
rodegenerative diseases such as Alzheimer’s. On the Island of 
Guam, many of the native villagers, known as Chamorros, suffer 
from a debilitating neurodegenerative disease with symptoms 
similar to Alzheimer’s disease, amyotrophic lateral sclerosis 
(ALS), and Parkinson’s disease (Cox et al., 2016). The illness 
caused paralysis, shaking, and dementia at 50-100 times the in-
cidence of ALS worldwide (Holtcamp 2012). This disease was 
first described in the 1950’s by US Army physicians, who called 
it amyotrophic lateral sclerosis/Parkinsonism dementia complex 
(ALS/PDC). Amyloid-β plaques and neurofibrillary tangles were 
present in the brains of Chamorros who developed this mys-
tery disease. Although in some villages a quarter of adults died 
from this disease, no distinct pattern of heredity was apparent. 
Because outsiders who adopted the Chamorro lifestyle were 
also affected, the cause of this disease seemed likely to be an 
environmental toxin (Cox et al., 2016).
The BMAA Hypothesis
There was difficulty in determining the exact nature of the 
toxin because symptoms could appear years after the expo-
sure. However, researchers were able to isolate the neurotox-
in β-N-methylamino-L-alanine (BMAA) from the cycad seed, 
which the Chamorros use to make flour, a staple in their diet. In 
the 1980’s, BMAA was fed to macaques which caused acute neu-
rological symptoms. However, these results were disregarded 
when it was shown that a human would have to consume an 
inordinate amount of cycad seed flour to ingest a comparable 
dose (Cox et al., 2016). Paul Alan Cox, an ethnobotanist, arrived 
in Guam in the 1990’s and revived the hypothesis that BMAA 
causes ALS/PDC seen in the natives (Holtcamp 2012). With 
his colleague Sandra Banack, he was able to show that BMAA 
was produced by a symbiotic cyanobacteria living in specialized 
cycad roots. BMAA accumulates in the gametophytes of the 
cycad seeds that are ground and eaten by the villagers. Cox then 
showed that animals such as flying foxes, feral deer, and pigs all 
feed on the cycad seeds, which are then eaten by the Chamorro 
people. BMAA is biomagnified in these mammals 10, 000 times 
that which is produced by the cyanobacteria. This process of 
biomagnification allows a sufficiently toxic amount of BMAA 
to accumulate in the food chain that it can cause neurological 
symptoms in the Chamorro people. This problem is not limited 
to Guam. BMAA producing cyanobacteria live in many marine 
ecosystems that biomagnify BMAA up the food chain, accumu-
lating in sharks, bottom-dwelling fish, and shellfish (Cox et al., 
2016). People who eat these organisms are at risk of BMAA 
ending up in their brain tissue.
Mechanism of Toxicity of BMAA
BMAA is readily able to cross the blood-brain barrier into 
the brain and central nervous system. It is mistaken for 
L-serine by the cellular mechanism and misincorporated into 
proteins, leading to misfolding, aggregation, and apoptosis of 
the cell (Cox et al., 2016). In normal proteins, the hydrophilic 
part is on the outside of the structure and the hydrophobic 
part is on the inside. However, because of protein misfolding 
due to the incorporation of BMAA, the hydrophobic part can 
end up on the outside, exposed. These hydrophobic areas are 
sticky and tend to clump together forming the characteristic 
aggregates of neurodegenerative plaques. These small aggre-
gates end up forming larger ones that prevent the cells from 
functioning properly (Holtcamp 2012). A misincorporation 
rate of even 1 in 10,000 has been shown to have a neurode-
generative effect in laboratory animals. BMAA can also result 
in phosphorylated tau by activating mGluR5, a metabotropic 
glutamate receptor, which decreases the activity of protein 
phosphatase 2A (PP2A). PP2A is significantly decreased in 
Chamorro ALS/PDC brains, resulting in an increase of phos-
phorylated tau (Cox et al., 2015).
Neuropathology Caused by BMAA in an 
Animal Model
To further prove that BMAA is responsible for the neuro-
degenerative disease, Cox and his colleagues conducted an 
experiment in which they attempted to show that chronic 
exposure to BMAA causes neuropathology and that BMAA 
can be re-isolated from the induced organisms. Vervets, a type 
Figure 1: Mechanism of prion mediated misfolding of protein  
(Sanders 2015
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of non-human primate, were the subject of this study. The 
vervets in this experiment were exposed to L-BMAA in their 
diets for 140 days, and then the brain tissue was examined for 
tau and amyloid deposition. Sixteen juvenile vervets divided 
into 4 cohorts of 4 were used in this experiment. The first 
cohort of vervets was given a piece of fruit dosed with 651 
mg of L-BMAA. Because L-serine has been shown to prevent 
misincorporation of BMAA into proteins, a cohort was given 
was given 651mg of L-BMAA and 651 mg of L-serine. A third 
cohort was given just 651 mg of L-serine. Finally, a control 
group was given a piece of fruit with 651 mg of rice flour as 
a placebo. A second experiment was done using adult vervets, 
also using four cohorts. The first cohort was given 987 mg of 
L-BMAA. The second was given 98.7 mg of L-BMAA, a tenfold 
reduction. The third was given 987 mg of L-BMAA, and 987 mg 
of L-serine. The fourth, a control, had 987 mg of rice flour as a 
placebo (Cox et al., 2016). 
In the first experiment, the vervets that received L-BMAA 
had neurofibrillary tangles and sparse amyloid-β plaque 
buildup in many areas of the brain. In contrast, the cohort 
that received L-serine and the control cohort did not show 
signs of amyloid-β or tau inclusions. The cohort that received 
an equal amount of L-BMAA and L-serine showed an 80-90% 
reduction in amyloid-β plaques and neurofibrillary tangles. 
In the second experiment, all BMAA exposed vervets de-
veloped hyperphosphorylated tau proteins and neurofibril-
lary tangles. The density of the neurofibrillary tangles in the 
brain was clearly related to the dose of BMAA administered. 
Besides for the control cohort, the low dose cohort had 
the lowest median count of neurofibrillary tangle density; the 
median density of the high dose cohort was more than twice 
the levels of the low dose cohort. The cohort that received 
both high dose BMAA and L-serine had a 50% decrease of 
neurofibrillary tangles compared to the high dose cohort. 
Exposure to BMAA also increased the chances of developing 
amyloid-β deposits, which were not found in any of the con-
trol vervets (Cox et al., 2016).
This study shows that dietary exposure to BMAA can cause 
the formation of neurofibrillary tangles and deposition of 
amyloid-β (Figure 2).  BMAA-producing cyanobacteria live 
worldwide and can have an important effect on human 
health. BMAA may possibly act as an initiator for sporadic 
Alzheimer’s disease by triggering the formation of amyloid 
plaques and neurofibrillary tangles. This study also indicates 
that L-serine is able to reduce the risk of formation of the 
characteristic plaques and tangles in the brains tissue of af-
fected individuals, and that L-serine may have a possible ther-
apeutic role in the treatment of mild cognitive impairment 
and early Alzheimer’s disease (Cox et al., 2016).
Conclusion
This paper investigated three seemingly unrelated mechanisms 
that have been proposed to cause the neuropathology seen in 
Alzheimer’s disease. Although the means of each method re-
viewed are very different, they have all been studied as a po-
tential cause of the buildup of the characteristic plaques and 
tangles present in the disease. Alzheimer’s disease is a public 
health problem; it is the sixth-leading cause of death in the 
United Stated, and fifth among people 65 and older (Alzheimer’s 
Association). Therefore it is important to study various models 
of the mechanism of the disease in the hope of gaining a better 
understanding of it, and eventually finding a cure. These three 
models may seem disconnected from each other, but in reality, 
Alzheimer’s disease is a complex disease. There are multiple fac-
tors involved that cause a person to develop Alzheimer’s related 
neurodegeneration; there is no one “correct” model. The three 
mechanisms discussed are only part of the multipart picture, 
and yet they are important to understand to get a complete 
understanding of the various pathways that lead to this disease. 
Figure 2: Theoretical pathways of development of ALS/PDC and 
Alzheimer’s disease neuropathology from dietary BMAA exposure 




By examining different routes, hopefully some light will be shed 
on questions like; why, if two people have a genetic predisposi-
tion, does one develop Alzheimer’s and one does not? Only by 
studying the causes will we ever discover a cure to the disease 
that affects so many.
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